An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds)
Latest Information Update: 06 May 2022
At a glance
- Drugs V 503 (Primary)
- Indications Anal cancer; Cervical cancer; Condylomata acuminata; Human papillomavirus infections; Vulvovaginal cancer
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme; sanofi pasteur MSD
- 03 Mar 2021 Results published in the Vaccine
- 23 Mar 2019 This trial has been completed in Finland, according to European Clinical Trials Database.
- 23 Mar 2019 This trial has been completed in Spain, according to European Clinical Trials Database.